Ionis Pharmaceuticals Inc
(NAS:IONS)
$
35.91
-0.42 (-1.16%)
Market Cap: 5.74 Bil
Enterprise Value: 4.73 Bil
PE Ratio: 0
PB Ratio: 8.65
GF Score: 40/100 Ionis Pharmaceuticals Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 04, 2023 / 02:45PM GMT
Release Date Price:
$35.35
Operator
You may begin.
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
All right. Good morning, and thank you for joining us on Guggenheim's Genomic Medicine and Rare Disease conference, day 2. This is the fifth iteration. I am Debjit and I'm one of the covering analysts at Guggenheim. My privilege to welcome Ionis Pharmaceuticals Executive Vice President of Research, Eric Swayze. Good morning, Eric. Thank you for your time today.
Eric E. Swayze
Ionis Pharmaceuticals, Inc. - EVP of Research
Good morning, and thanks for having me on your show. Appreciate being here.
Questions & Answers
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Well not much of a show, but let's get on with the Q&A then. I mean, obviously, given the depth and breadth of the pipeline and the recent positive - [go over] some panel votes, any key programs you would like -- or the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot